Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / IL6



This biomarker is also known as:
  • interleukin 6 (interferon, beta 2),
  • IFNB2,
  • HSF,
  • BSF2,
  • IL-6,
  • Interleukin 6,
  • B-cell differentiation factor,
  • BSF-2,
  • CTL differentiation factor,
  • CDF,
  • B cell stimulatory factor-2,
  • HGF,
  • Hybridoma growth factor,
  • IFN-beta-2,
  • Interferon beta-2,
  • B-cell stimulatory factor 2,

View in BioMuta


Interleukin 6 (IL6) is a cytokine that is involved in inflammation and the maturation of B cells as well as induction of the acute phase response. In addition to inducing myeloma and plasmacytoma growth and nerve cell differentiation, it also plays an important role in the differentiation of B-cells into Ig-secreting cells involved in lymphocyte and monocyte differentiation. The IL6 protein is produced mainly at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The IL6 gene is involved in many inflammation-associated disease states, including diabetes mellitus, where it acts on insulin resistance, and systemic juvenile rheumatoid arthritis. IL6 is discharged into the bloodstream after muscle contraction.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: IL6


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


IL6 alone is not a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.